Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 3 INNOVATION Confident in future growth driven by our strength and depth in cardio-renal, immunology, neuroscience... Selected assets Cardio-renal Immunology CosentyxⓇ Neuroscience Ⓡ HS: Ph3 SUNRISE, SUNSHINE readout H2 2021 Zolgensma SMA IT: FDA hold lifted, Ph3 initiating LeqvioⓇ Hyperlipidemia: FDA action date January 1, 2022 GCA: Ph2 readout positive CVRR-LDLC: Ph3 ongoing jPSA/ERA (submitted), lupus nephritis (Ph3), lichen planus (Ph2) Branaplam Huntington's disease: Ph2b start H2 2021 Iptacopan IgAN, C3G, aHUS: Ligelizumab CSU: Ph3 PEARL 1, 2 readout 20211 Ph3s started 2021 iMN: Ph2b ongoing Pelacarsen CVRR-Lp(a): Ph3 ongoing Other indications being explored lanalumab Sjögren's, SLE, Autoimmune hepatitis: Ph2s ongoing Iscalimab Sjögren's, liver Tx, HS: Ph2s ongoing CINDU, food allergy²: Ph3 starts H2 2021 Remibrutinib CSU: Ph2 data positive Remibrutinib Multiple sclerosis: Ph3 start H2 2021 'Wild Cards' LNA043 (osteoarthritis: Ph2 ongoing), CSJ117 (asthma: Ph2 ongoing, COPD Ph2 started), QBW251 (COPD: Ph2 recruitment completed), SAF312 (COSP: Ph2 SAHARA ongoing), UNR844 (presbyopia: Ph2 READER ongoing) 1. Q4/2021-Q1/2022 potential COVID-19 impact 2. Food Allergy indication falls within the Respiratory & Allergy therapeutic area 14 Investor Relations | Q3 2021 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation